Mirecule, Inc

Mimetas is a leading company in Gaithersburg, MD that specializes in drug discovery and preclinical research. They offer a range of resources and support for scientists, partners, and customers worldwide, including peer-reviewed publications, blogs, case studies, webinars, and events. With their innovative 3D tissue culture technology, Mimetas is revolutionizing drug discovery by providing unmatched disease relevance, precision, throughput, and ethical commitment. Their organ-on-a-chip technology recreates physiologically relevant environments on a large scale, making them a trusted partner for global pharmaceutical and biotech companies. Mimetas is dedicated to advancing preclinical predictivity with their human organ models, supporting ADME and safety with enhanced translatability while minimizing reliance on animal models. They offer a wide range of preclinical research applications, including perfused tubules, 3D cell migration, vascularization, and cell-cell interactions. With 10 years of impactful science, Mimetas is committed to leveraging their 3D tissue expertise to provide tailored answers to unique research questions. Their state-of-the-art modeling technologies enable collaborations in drug discovery, prioritization and optimization, and compound analysis. The quality and value they offer have earned them the trust of leading global pharmaceutical and biotech companies.Generated from the website

EzBiome Inc is a Gaithersburg-based company specializing in rapid detection, mutation analysis, and epidemiology subtyping of SARS-CoV-2, as well as offering bioinformatics sequencing services for microbiome and isolate sequencing. With a focus on bacterial and fungal identification, EzBiome Inc provides comprehensive resources and expertise in the field of bioinformatics, catering to both laboratory and industrial needs.Generated from the website

Novavax is a biotechnology company focused on the research, development and commercialization of products utilizing its proprietary drug delivery solutions. The company's drug delivery technologies include Novasomes, Sterisomes and micellar nanoparticle technology, which is the basis for the development of the federally approved product, ESTRASORB. Novavax s vaccine technologies include its virus-like particle manufacturing technology, utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes and dendrimer technologies. In 2006, Kleiner Perkins Caufield & Byers acquired $12.5 million worth of Novavax s common stock, and Prospect Venture partners acquired $7.5 million worth of the company s common stock, which is in addition to the $5.5 million of previously accumulated equity it had purchased in the open market. Novavax is headquartered in Malvern, Pa.